laromestrocel (LOMECEL-B®) — NDA/BLA submission
2027
If the current ELPIS II trial in HLHS is successful, we believe the timing would be optimal to seek a potential BLA filing with the FDA in 2027 and commercialization partner.Source filing
LGVN biotech catalysts & pipeline
LONGEVERON INC · Data as of 2026-10-25
Upcoming catalysts
laromestrocel (LOMECEL-B®) — Conference presentation
Q4 2026
Longeveron has been invited to participate in six upcoming longevity focused investor conferences in the fourth quarter of 2026.Source filing